September 28, 2020

The Niche

Knoepfler lab stem cell blog

AMD stem cells

9 min read

Masayo Takahashi (高橋 政代) on IPSC Trial for Macular Degeneration By Michael Cea Stem Cell Analyst & Advocate (editor’s note: piece was originally posted on Michael’s blog here; follow Michael on Twitter @msemporda) Having followed closely the developments in programs using pluripotent based therapeutics I was fortunate during ISSCR2015 to have the opportunity to sit down with Dr Masayo Takahashi to discuss her pioneering efforts to translate Shinya Yamanaka’s groundbreaking iPS technology for debilitating retinal conditions. As most everyone is aware, the first iteration of the …Read More

5 min read

I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has generated a great deal of excitement. Can you please share your perspectives on the importance of this work and the team involved?  SY: This is the first study to apply …Read More

13 min read

StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought were some tough questions from me and very detailed answers from Shiffman. Thank you, Greg. 1. Where does the company stand today in terms of product development, capitalization, and …Read More